24.42 USD
-0.05 (-0.2%)
24.42 USD
0 (0%)
BLFS gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year BLFS was profitable.
- In the past year BLFS had a positive cash flow from operations.
- BLFS had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
1.2 Ratios
- With a Return On Assets value of -0.82%, BLFS perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
- BLFS has a better Return On Equity (-0.91%) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BLFS has a better Gross Margin (70.02%) than 92.98% of its industry peers.
- In the last couple of years the Gross Margin of BLFS has remained more or less at the same level.
- BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
- BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BLFS has more shares outstanding
- Compared to 5 years ago, BLFS has more shares outstanding
- Compared to 1 year ago, BLFS has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 17.67 indicates that BLFS is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 17.67, BLFS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- There is no outstanding debt for BLFS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.67 |
ROIC/WACCN/A
WACC11.06%
2.3 Liquidity
- BLFS has a Current Ratio of 4.66. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 4.66, BLFS is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
- BLFS has a Quick Ratio of 3.64. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
- BLFS has a Quick ratio of 3.64. This is in the better half of the industry: BLFS outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
- BLFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.36%, which is quite impressive.
- Looking at the last year, BLFS shows a very negative growth in Revenue. The Revenue has decreased by -24.98% in the last year.
- Measured over the past years, BLFS shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
3.2 Future
- The Earnings Per Share is expected to grow by 29.91% on average over the next years. This is a very strong growth
- BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.63% yearly.
EPS Next Y32.33%
EPS Next 2Y47.65%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue Next Year-10.81%
Revenue Next 2Y1.83%
Revenue Next 3Y8.04%
Revenue Next 5Y15.63%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 97.68 indicates a quite expensive valuation of BLFS.
- Compared to the rest of the industry, the Price/Earnings ratio of BLFS is on the same level as its industry peers.
- When comparing the Price/Earnings ratio of BLFS to the average of the S&P500 Index (27.38), we can say BLFS is valued expensively.
- A Price/Forward Earnings ratio of 266.01 indicates a quite expensive valuation of BLFS.
- The rest of the industry has a similar Price/Forward Earnings ratio as BLFS.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, BLFS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.68 | ||
| Fwd PE | 266.01 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as BLFS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 221.52 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- BLFS's earnings are expected to grow with 40.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.02
PEG (5Y)N/A
EPS Next 2Y47.65%
EPS Next 3Y40.1%
5. Dividend
5.1 Amount
- No dividends for BLFS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
24.42
-0.05 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)05-06 2026-05-06
Inst Owners103.55%
Inst Owner Change-0.11%
Ins Owners2%
Ins Owner Change-1.39%
Market Cap1.18B
Revenue(TTM)88.83M
Net Income(TTM)-3.21M
Analysts83.75
Price Target32.87 (34.6%)
Short Float %5.9%
Short Ratio8.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)128.28%
Min EPS beat(2)72.55%
Max EPS beat(2)184.01%
EPS beat(4)4
Avg EPS beat(4)208.62%
Min EPS beat(4)72.55%
Max EPS beat(4)496.49%
EPS beat(8)7
Avg EPS beat(8)84.53%
EPS beat(12)8
Avg EPS beat(12)5.02%
EPS beat(16)10
Avg EPS beat(16)1.09%
Revenue beat(2)2
Avg Revenue beat(2)6.11%
Min Revenue beat(2)5.11%
Max Revenue beat(2)7.1%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.34%
Max Revenue beat(4)7.1%
Revenue beat(8)7
Avg Revenue beat(8)8.78%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.21%
PT rev (1m)0.38%
PT rev (3m)2.95%
EPS NQ rev (1m)-8.35%
EPS NQ rev (3m)-160.14%
EPS NY rev (1m)0%
EPS NY rev (3m)4.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.83%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-6.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.68 | ||
| Fwd PE | 266.01 | ||
| P/S | 13.24 | ||
| P/FCF | N/A | ||
| P/OCF | 69.81 | ||
| P/B | 3.32 | ||
| P/tB | 8.78 | ||
| EV/EBITDA | 221.52 |
EPS(TTM)0.25
EY1.02%
EPS(NY)0.09
Fwd EY0.38%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.35
OCFY1.43%
SpS1.84
BVpS7.35
TBVpS2.78
PEG (NY)3.02
PEG (5Y)N/A
Graham Number6.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.02% | ||
| FCFM | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 298.5% | ||
| Cap/Sales | 19.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 353.72% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.66 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 17.67 |
F-Score6
WACC11.06%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y32.33%
EPS Next 2Y47.65%
EPS Next 3Y40.1%
EPS Next 5Y29.91%
Revenue 1Y (TTM)-24.98%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-8.19%
Revenue Next Year-10.81%
Revenue Next 2Y1.83%
Revenue Next 3Y8.04%
Revenue Next 5Y15.63%
EBIT growth 1Y95.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year325.11%
EBIT Next 3Y89.24%
EBIT Next 5YN/A
FCF growth 1Y97.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y342.36%
OCF growth 3YN/A
OCF growth 5Y47.44%
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the ChartMill fundamental rating of BIOLIFE SOLUTIONS INC (BLFS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BLFS.
Can you provide the valuation status for BIOLIFE SOLUTIONS INC?
ChartMill assigns a valuation rating of 2 / 10 to BIOLIFE SOLUTIONS INC (BLFS). This can be considered as Overvalued.
Can you provide the profitability details for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for BLFS stock?
The Price/Earnings (PE) ratio for BIOLIFE SOLUTIONS INC (BLFS) is 97.68 and the Price/Book (PB) ratio is 3.32.
What is the expected EPS growth for BIOLIFE SOLUTIONS INC (BLFS) stock?
The Earnings per Share (EPS) of BIOLIFE SOLUTIONS INC (BLFS) is expected to grow by 32.33% in the next year.